Prevention of Clostridium difficile infection with Saccharomyces boulardii: A systematic review

Canadian Journal of Gastroenterology

Volumn 23, Issue 12, 2009, Pages 817-821

  Tung, Jennifer M ^a   Dolovich, Lisa R ^a   Lee, Christine H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

C difficile infection; Probiotic; Saccharomyces boulardii

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN;

BACTERIUM CULTURE; CINAHL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBASE; HUMAN; INFORMATION RETRIEVAL; LOW DRUG DOSE; MEDLINE; PNEUMATOSIS INTESTINALIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SACCHAROMYCES BOULARDII; SECONDARY PREVENTION; SIDE EFFECT; SYSTEMATIC REVIEW; THIRST; TREND STUDY;

EID: 73349142966     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/915847     Document Type: Review

References (15)

1. Stoddart B, Wilcox MH. Clostridium difficile. Curr Opin Infect Dis 2002;5:513-8.
2. Malnick SDH, Zimhony O. Treatment of Clostridium difficileassociated diarrhea. Ann Pharmacother 2002;36:1767-75.
3. McFarland LV, Surawicz CM, Greenberg, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
4. Pepin J, Valiquette L, Alary M-E. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171:466-72.
5. Eddy JT, Stamatakis MK, Makela EH. Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis. Ann Pharmacother 1997;31:919-21.
6. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2004;41:5340-3.
7. Popoola J, Swanna A, Warwick G. Clostridium difficile in patients with renal failure - management of an outbreak using biotherapy. Nephrol Dial Transplant 2000;15:571-4.
8. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36:171-4.
9. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.
10. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 1989;96:981-8.
11. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48.
12. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer G, Greenberg RN. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 2004;20:43-50.
13. Wilcox MH, Dave J. Treatment options in Clostridium difficile infection. Rev Med Microbiol 2001;12:21-8.
14. Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989;84:1285-7.
15. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. BMJ 2002;324:1361-6.